Tyra Biosciences (TYRA) Capital Expenditures (2020 - 2026)
Quarterly Capital Expenditures rose 42.86% to $20000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $74000.0 through Mar 2026, up 160.66% year-over-year, with the annual reading at $68000.0 for FY2025, N/A changed from the prior year.
Tyra Biosciences filings provide 7 years of Capital Expenditures readings, the most recent being $20000.0 for Q1 2026.
- Capital Expenditures hit $20000.0 in Q1 2026 for Tyra Biosciences, down from $43000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $470000.0 in Q2 2024 and bottomed at -$658000.0 in Q4 2024.
- Average Capital Expenditures over 5 years is $12529.4, with a median of $31000.0 recorded in 2025.
- Peak annual rise in Capital Expenditures hit 993.02% in 2024, while the deepest fall reached 1466.67% in 2024.
- Tyra Biosciences' Capital Expenditures stood at -$9000.0 in 2022, then tumbled by 366.67% to -$42000.0 in 2023, then plummeted by 1466.67% to -$658000.0 in 2024, then skyrocketed by 106.53% to $43000.0 in 2025, then plummeted by 53.49% to $20000.0 in 2026.
- Per Business Quant, the three most recent readings for TYRA's Capital Expenditures are $20000.0 (Q1 2026), $43000.0 (Q4 2025), and -$20000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 230.60 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Tyra Biosciences | 2.03 Bn | 2.03 Bn | - | 20,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20,000.00 |
| Mar 31, 2026 | 20,000.00 |
| Dec 31, 2025 | 43,000.00 |
| Dec 31, 2025 | 43,000.00 |
| Sep 30, 2025 | -20,000.00 |
| Sep 30, 2025 | -20,000.00 |
| Jun 30, 2025 | 31,000.00 |
| Jun 30, 2025 | 31,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Mar 31, 2025 | 14,000.00 |
| Dec 31, 2024 | -658,000.00 |
| Dec 31, 2024 | -658,000.00 |
| Sep 30, 2024 | 52,000.00 |
| Sep 30, 2024 | 52,000.00 |
| Jun 30, 2024 | 470,000.00 |
| Jun 30, 2024 | 470,000.00 |
| Mar 31, 2024 | 136,000.00 |
| Mar 31, 2024 | 136,000.00 |
| Dec 31, 2023 | -42,000.00 |
| Dec 31, 2023 | -42,000.00 |
| Sep 30, 2023 | 83,000.00 |
| Sep 30, 2023 | 83,000.00 |
| Jun 30, 2023 | 43,000.00 |
| Jun 30, 2023 | 43,000.00 |
| Mar 31, 2023 | 41,000.00 |
| Mar 31, 2023 | 41,000.00 |
| Dec 31, 2022 | -9,000.00 |
| Dec 31, 2022 | -9,000.00 |
| Sep 30, 2022 | -20,000.00 |
| Sep 30, 2022 | -20,000.00 |
| Jun 30, 2022 | -210,000.00 |
| Jun 30, 2022 | -210,000.00 |
| Mar 31, 2022 | 239,000.00 |
| Mar 31, 2022 | 239,000.00 |
| Dec 31, 2021 | 644,000.00 |
| Dec 31, 2021 | 644,000.00 |
| Sep 30, 2021 | -109,000.00 |
| Sep 30, 2021 | -109,000.00 |
| Jun 30, 2021 | 66,000.00 |
| Jun 30, 2021 | 66,000.00 |
| Mar 31, 2021 | 60,000.00 |
| Mar 31, 2021 | 60,000.00 |
| Dec 31, 2020 | -241,000.00 |
| Dec 31, 2020 | -241,000.00 |